Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.731598
Keywords
immunogenic cell death and anti-tumor immunity; pyroptosis; necroptosis; anti-tumor immune responses; tumor immune microenvironment; inflammation and immunity
Categories
Funding
- Agence Nationale de la Recherche (ANR) [ANR-20-CE92-0011]
- Deutsche Forschungsgemeinschaft (DFG) [BU1310/9-1]
Ask authors/readers for more resources
Cancer, the second leading cause of death globally, is often treated with chemotherapeutic drugs which can have side effects, but some of these drugs can stimulate anti-tumor immune responses through the induction of immunogenic cell death. The study discusses the potential of inducing different forms of ICD to enhance immunogenicity and stimulate effective anti-tumor immune responses.
Cancer remains the second most common cause of death worldwide affecting around 10 million patients every year. Among the therapeutic options, chemotherapeutic drugs are widely used but often associated with side effects. In addition, toxicity against immune cells may hamper anti-tumor immune responses. Some chemotherapeutic drugs, however, preserve immune functions and some can even stimulate anti-tumor immune responses through the induction of immunogenic cell death (ICD) rather than apoptosis. ICD stimulates the immune system by several mechanisms including the release of damage-associated molecular patterns (DAMPs) from dying cells. In this review, we will discuss the consequences of inducing two recently characterized forms of ICD, i.e., pyroptosis and necroptosis, in the tumor microenvironment (TME) and the perspectives they may offer to increase the immunogenicity of the so-called cold tumors and to stimulate effective anti-tumor immune responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available